CytoGenix, Inc. company was founded in 1995 and is based in Houston, Texas. CytoGenix, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of its proprietary technologies for identifying and silencing disease causing genes; and expressing proteins for applications, such as vaccines and isolating novel nucleic acid-based anti-microbial compounds. The company’s technologies include gene silencing techniques (ssDNA) applicable to genes from pathogenic organisms or selected genes from a patient to prevent the expression of harmful proteins; a novel, cell free process to produce large quantities of DNA (synDNA) for use in its own products and for sale to other biopharmaceutical or life science companies; and a methodology to isolate and characterize novel DNA-based drugs (Oligogenix) to which harmful bacteria have not developed resistance. Its products under development include SIMPLIVIR, an anti-herpes topical compound; Oligogenix technique based compounds against methicillin and vancomycin resistant staphylococcus aureus; and DNA vaccines for use in humans, poultry, aquaculture, and cattle. The company in collaboration with the United States Department of Agriculture, engages in a project to develop a synDNA based vaccine against brucellosis, a zoonotic disease which is easily transmitted from animals to humans.

PRA International knows it takes more than laboratory research to get drugs approved. The company, a clinical research organization (CRO), provides an array of drug development services to pharmaceutical and biotech companies around the world. Services the company offers include clinical trials management, database development, and regulatory filings preparation. PRA's clients are engaged in most major therapeutic areas, but the firm's particular strengths lie in oncology, central nervous system disorders, cardiovascular disease, allergy and respiratory disorders, and infectious disease. The company is owned by private equity firm Genstar Capital.

Glycotex wants to see such creatures as ulcers, bed sores, and sunburns put on the Australian endangered species list. The biopharmaceutical company researches and develops products based on molecular glucan receptors that trigger the healing process. Connective tissue repair, skin ulcers, and bone fractures are primary recovery fields for its glucan receptor products. Glycotex's lead product candidate, MG3601, is a topical treatment for ulcers, and it has completed Phase II clinical trials. Other therapeutic candidates include Glucocol and Glucoprime, active ingredients designed to treat tendon regeneration and topical needs, respectively. Its parent company, Novogen, owns 84% of Glycotex.

Genzyme and Medtronic are out to prove that it doesn't just take time to heal a broken heart. The two companies' joint venture, MG Biotherapeutics, was created in 2004 to develop new treatments for heart attacks and other cardiovascular conditions. The company in 2006 ceased enrollment of new patients in its Phase II clinical trial, which had been testing the use of cell therapy to repair damaged heart tissue following a heart attack, after evidence showed the trial would not be successful. MG Biotherapeutics is also engaged in long-term research into next-generation cell therapies and is developing a less-invasive, catheter-based delivery system for cell therapy using Medtronic's TransAccess technology.

Perrigo Company was founded in 1887 and is headquartered in Allegan, Michigan. Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients, and pharmaceutical and medical diagnostic products. The Company operates in three segments: Consumer Healthcare, Rx Pharmaceuticals and API. The Company has other category that consists of the Israel Pharmaceutical and Diagnostic Products. The Company operates through wholly owned subsidiaries. In the United States, its operations are conducted through L. Perrigo Company, Perrigo Company of South Carolina, Inc., Perrigo New York, Inc., Perrigo Holland, Inc. and Perrigo Florida, Inc. Outside the United States, its operations are conducted through Perrigo Israel Pharmaceuticals Ltd., Chemagis Ltd., Quimica y Farmacia S.A. de C.V., Laboratorios Diba, S.A., Wrafton Laboratories Limited, Brunel Pharma Limited and Galpharm Healthcare Ltd.

Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland. Sucampo Pharmaceuticals, Inc., through its subsidiaries, focuses on the discovery, development, and commercialization of drugs based on prostones in the United States, Europe, and Japan. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of glaucoma. In addition, Sucampo Pharmaceuticals is conducting two Phase III pivotal trials of Amitiza for opioid-induced bowel dysfunction; a Phase II proof of concept trial of Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers; various preclinical trials of Cobiprostone for cystic fibrosis respiratory symptoms, topical ulcers and wounds, and chronic obstructive pulmonary disease; and a preclinical phase study of SPI-017 for Alzheimer's disease. The company also has various pre-clinical studies of six additional preclinical prostone compounds, including two combination candidates for age-related diseases.

Spectrum Pharmaceuticals, Inc. operates as a commercial-stage biotechnology company with a primary focus in oncology market. The company focuses on acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products. Its marketed products include ZEVALIN, a form of cancer therapy called radioimmunotherapy for the treatment of non-Hodgkin's Lymphoma; and FUSILEV, which is indicated after high-dose methotrexate therapy in patients with osteosarcoma. The company also develops apaziquone for the treatment of non-muscle invasive bladder cancer. Its phase II products comprise Ozarelix, a drug being investigated for benign prostatic hypertrophy, a non-cancerous enlargement of the prostate; and Ortataxel, a third-generation taxane. In addition, Spectrum Pharmaceuticals, Inc. has exclusive worldwide rights to Renazorb, Renalan, and related compounds. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Irvine, California.

MAP Pharmaceuticals was founded in 2003 and is headquartered in Mountain View, California. MAP Pharmaceuticals, Inc., a development stage company, engages in developing drug candidates to treat local respiratory and treatable diseases primarily in the United States. The company develops inhalable drug particles to facilitate pulmonary delivery. Its proprietary product candidates in clinical development include Unit Dose Budesonide, a nebulized version of budesonide for the treatment of asthma in children; and MAP0004, an orally inhaled version of dihydroergotamine for the treatment of migraine. MAPP company's product portfolio also includes the earlier stage product candidates, which include MAP0005, an inhaled corticosteroid and beta-agonist for the treatment of asthma and chronic obstructive pulmonary disease; and MAP0001, a formulation of insulin for the treatment of Type 1 and Type 2 diabetes through pulmonary delivery using Tempo inhaler. It has a collaborations and license agreements with AstraZeneca, Elan Pharma International, Nektar Therapeutics, and Xemplar Pharmaceuticals.

Arrow Therapeutics was founded in 1998; AstraZeneca acquired the firm in 2007. Arrow Therapeutics is a pharmaceutical product discovery company that is researching new anti-infective medicines. The company's top candidate is RSV604, an antiviral molecular program to combat respiratory syncytial virus (RSV), a leading cause of respiratory infections worldwide. This candidate is currently undergoing clinical trials and has been licensed to Novartis. Other leading programs include compounds developed to fight infectious dieseases such as Hepatitis C, herpes, and chicken pox.

Renovo was established in 2000 by Professor Mark Ferguson and Doctor Sharon O'Kane. Renovo had its way, that famous scar on Harry Potter would be gone in no time. The pharmaceutical company develops drug products designed to prevent scarring caused by skin or cosmetic surgeries, eye injuries, adhesions, tendon and ligament damage, and nerve damage (no word yet on if it helps treat the blemishes of boy wizards). Renovo's chief product is Juvista, a trial stage drug that is injected into the edges of wounds to help prevent scars. The company also has three other pre-clinical drug products in development: Juvidex (for scar improvement), Prevascar (scar reduction), and Zesteem (skin healing).

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.